Poseida Therapeutics Inc
(FRA:2RZ)
€
3.034
-0.01 (-0.33%)
Market Cap: 301.96 Mil
Enterprise Value: 197.15 Mil
PE Ratio: 0
PB Ratio: 3.88
GF Score: 36/100 - Poseida Therapeutics Inc P-BCMA-ALLO1 Clinical Data Call TranscriptDec 10, 2023
- Poseida Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 26, 2023
- Poseida Therapeutics Inc at Stifel Tailoring Genes: Genetic Medicines Day (Virtual) TranscriptMay 30, 2023
- Poseida Therapeutics Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Poseida Therapeutics Inc at HC Wainwright Cell Therapy Virtual Conference TranscriptFeb 28, 2023
- Poseida Therapeutics Inc at Piper Sandler Healthcare Conference TranscriptNov 30, 2022
- Poseida Therapeutics Inc at Stifel Healthcare Conference TranscriptNov 16, 2022
- Poseida Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 12, 2022
- Poseida Therapeutics Inc Collaboration and Poseida's Novel Approach to Allogeneic Cell Therapy - Corporate Call TranscriptAug 03, 2022
- Poseida Therapeutics Inc at Bank of America Healthcare Conference TranscriptMay 10, 2022
Poseida Therapeutics Inc at Stifel Tailoring Genes: Genetic Medicines Day (Virtual) Transcript
May 30, 2023 / 07:00PM GMT
Release Date Price:
€2.2
(+0.92%)
Ben Burnett
Stifel Financial Corp. - Analyst
Okay. Welcome, everyone, to our next panel. I'm Ben Burnett with Stifel Research. And I'm pleased to be here with Poseida Therapeutics. Brent Warner, President of Gene Therapy. Thanks for being here.
Brent Warner
Poseida Therapeutics, Inc. - President, Gene Therapy
Yeah, thank you for having us, Ben. Nice to be here.
Ben Burnett
Stifel Financial Corp. - Analyst
Awesome. Let's start off. Can you give us just a brief intro of the company from a gene therapy perspective, gene editing perspective and just highlight through the near-term event path?
Brent Warner
Poseida Therapeutics, Inc. - President, Gene Therapy
Yeah, absolutely. So my name is Brent Warner, President of Gene Therapy at Poseida. Just for background, I've worked on some of the most advanced gene therapies at Novartis and BioMarin and other companies. And really excited to see the technology underpinning Poseida.
So we are a genetic engineering
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)